In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vertex picks up global rights to two HCV candidates from Alios; Vertex ends HCV program

Executive Summary

Alios BioPharma Inc. (antivirals) has licensed Vertex Pharmaceuticals Inc. (treatments for hepatitis C, cystic fibrosis, epilepsy, and other conditions) exclusive worldwide rights to the preclinical hepatitis C nucleotide analogues ALS2200 and ALS2158.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies